Barclays PLC increased its position in Omeros Co. (NASDAQ:OMER - Free Report) by 121.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,640 shares of the biopharmaceutical company's stock after buying an additional 51,873 shares during the quarter. Barclays PLC owned 0.16% of Omeros worth $376,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also added to or reduced their stakes in OMER. MML Investors Services LLC lifted its holdings in Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 3,000 shares during the period. State Street Corp raised its position in shares of Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock worth $4,867,000 after acquiring an additional 3,839 shares during the last quarter. HighTower Advisors LLC lifted its stake in shares of Omeros by 7.2% in the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company's stock worth $235,000 after acquiring an additional 4,000 shares during the period. Rhumbline Advisers boosted its holdings in Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company's stock valued at $454,000 after acquiring an additional 6,435 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 7,016 shares during the period. Institutional investors own 48.79% of the company's stock.
Omeros Price Performance
Shares of OMER stock traded up $1.37 on Friday, reaching $11.21. 759,623 shares of the company were exchanged, compared to its average volume of 684,712. The company has a 50-day moving average of $8.32 and a 200-day moving average of $5.62. The company has a market cap of $649.62 million, a price-to-earnings ratio of -4.85 and a beta of 1.97. Omeros Co. has a one year low of $2.61 and a one year high of $13.60.
Analyst Ratings Changes
A number of brokerages have recently issued reports on OMER. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They issued a "buy" rating and a $9.00 price target on the stock. RODMAN&RENSHAW raised shares of Omeros to a "strong-buy" rating in a research report on Thursday, November 14th. D. Boral Capital started coverage on Omeros in a research report on Monday, December 23rd. They issued a "buy" rating and a $36.00 price objective for the company. StockNews.com upgraded Omeros from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of Omeros in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Omeros currently has a consensus rating of "Moderate Buy" and a consensus price target of $22.50.
Check Out Our Latest Report on OMER
About Omeros
(
Free Report)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
See Also
Before you consider Omeros, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.
While Omeros currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
